Palatin Technologies, Inc. (PTNTD.PK), Monday announced that the company has reached a research milestone, worth 5.5 million euros, equivalent to $6.5 million, under its collaboration with Boehringer Ingelheim.
The collaboration with Boehringer Ingelheim was signed on August 18, 2025, to develop potential first-in-class melanocortin receptor-targeted treatments for patients with retinal diseases.
Commenting on the recent achievement, CEO Carl Spana said, "Melanocortin receptor agonists represent a differentiated and promising approach to address the underlying drivers of retinal diseases such as diabetic retinopathy and diabetic macular edema, which affect an estimated one in three people living with diabetes."
Currently, Palatin's stock is trading at $8.50, up 1.80 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.